中华肝脏病杂志最新文献

{"title":"[Tenofovir amibufenamide combined with pegylated interferon α-2b in treatment of chronic hepatitis B patients with low-level viremia: a case report].","authors":"D X He, S L Ma","doi":"10.3760/cma.j.cn501113-20240824-00388","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240824-00388","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"37-40"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tenofovir amibufenamide treatment for three cases with chronic hepatitis B].","authors":"M J Lyu, J Qiu","doi":"10.3760/cma.j.cn501113-20240903-00469","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240903-00469","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"76-78"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tenofovir amibufenamide treatment in a case of hepatitis B virus-related decompensated liver cirrhosis].","authors":"Y P Li, G E Gou, S S Dang","doi":"10.3760/cma.j.cn501113-20240906-00481","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240906-00481","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"54-55"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of complete viral suppression after switching to tenofovir amibufenamide treatment with chronic hepatitis B and concomitant impaired renal function].","authors":"J Li, B X Qian, Q Ye","doi":"10.3760/cma.j.cn501113-20240919-00499","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240919-00499","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"73-75"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Let's start from practical for returning academics to the clinic].","authors":"Y M Nan","doi":"10.3760/cma.j.cn501113-20241013-00536","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20241013-00536","url":null,"abstract":"<p><p>To standardize and improve the diagnosis and treatment level of chronic hepatitis B, clinical physicians should actively grasp the timing for initiating antiviral treatment, reasonably evaluate the selection of antiviral drugs, and pay close attention to the whole-process management of chronic HBV infection in their daily practice in order to reduce the risk of occurrence of serious diseases such as HCC. The concept of patient diagnosis and treatment plans should follow the treatment principles of the new version of the guidelines and formulate individualized treatment plans based on the actual situation of the patients. The development of academic activities and research should also start with solving problems found in practice or clinical needs so as to bring better diagnosis and treatment benefits to patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case report of mild hereditary hemochromatosis caused by HAMP gene mutation].","authors":"Z Wang, W Hou, H Zheng","doi":"10.3760/cma.j.cn501113-20240724-00345","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240724-00345","url":null,"abstract":"<p><p>The incidence of juvenile Hereditary Hemochromatosis caused by HAMP gene mutation is low, which is rarely reported in China. This patient took abnormal liver function as the first symptom, and was finally diagnosed by genetic testing and hepatic histopathology, and treated by venous bloodletting.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on the mechanism of Fuzheng Huayu formula against biliary fibrosis in mice].","authors":"Z Zhang, Y Liang, E Q Tang, X X Zhou, Y H Hu, G F Chen, W Liu, Y P Mu, P Liu, J M Chen","doi":"10.3760/cma.j.cn501113-20240815-00375","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240815-00375","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effect and mechanisms of Fuzheng huayu formula (FZHY) on biliary fibrosis in mice. <b>Methods:</b> <i>Mdr2</i> gene knowout (<i>Mdr2</i>^-/-) mice were randomly divided into model group, FZHY-treated group and obeticholic acid (OCA)-treated group. Wide type C57BL/6J (WT) mice of the same age were used as the control group. <i>Mdr2</i>^-/- mice were treated with the corresponding drugs by gavage from the first day of the 9^th week old. The WT and model groups were given 0.3% sodium carboxymethyl cellulose by gavage, and the mice were sacrificed at the end of 12^th week old. The activities of serum alkaline phosphatase (ALP) and alanine aminotransferase (ALT) were detected by high-speed biochemical analyzer. H&E staining and sirius red staining were used to observe the pathological changes of liver tissues. The hepatic hydroxyproline content was determined. The hepatic expressions of Col-Ⅰ and α-SMA, ductular reaction markers Epcam, CK7, CK19, and the expression of Pcna, Mki67 and Ccnd1; as well as the expression of inflammatory cytokines Ccl2, Ccl5, Tnf-α, Il10 and Cxcl4 were detected by immunohistochemical staining, western blot and qRT-PCR, respectively. Furthermore, the expression of PPARα and the phosphorylation NF-κB were detected by western blot. <b>Results:</b> Compared with WT mice, the serum ALT and ALP activities of <i>Mdr2</i>^-/- mice were significantly increased (<i>P</i><0.001). The percentage of SR positive stained area and hepatic Hyp content were significantly increased (<i>P</i><0.01). The hepatic expression of Col-Ⅰ and α-SMA; Epcam, CK7, CK19, Pcna, Mki67 and Ccnd1; Ccl2, Ccl5, Tnf-α, Il10 and Cxcl4 were significantly increased (<i>P</i><0.01). However, both FZHY and OCA significantly reversed the elevation of these aforementioned indicators (<i>P</i><0.05; <i>P</i><0.01). Further study showed that the hepatic expression of PPARα in <i>Mdr2</i>^-/- mice was significantly lower than that of WT mice, however the phosphorylation of NF-κB was significantly enhanced (<i>P</i><0.01). The expression of PPARα in liver tissues of FZHY mice was significantly increased (<i>P</i><0.05), and the NF-κB phosphorylation was significantly inhibited compared with <i>Mdr2</i>^-/- mice (<i>P</i><0.05). <b>Conclusion:</b> FZHY significantly ameliorated liver fibrosis, ductular reaction and inflammation in <i>Mdr2</i>^-/- spontaneous biliary fibrosis mice, and its mechanism was related to the regulation of PPARα/NF-κB pathway.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The nomogram model and its value study of Gd-EOB-DTPA enhanced MRI for preoperative diagnosis of proliferative hepatocellular carcinoma].","authors":"F X Chen, D J Guo, Y Xu, J Cheng, Y M Li, G L Chen, X M Li","doi":"10.3760/cma.j.cn501113-20240509-00246","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240509-00246","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To develop a nomogram model for preoperative diagnosis of proliferative hepatocellular carcinoma(HCC) based on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) enhanced magnetic resonance imaging (MRI), and to explore its clinical value. &lt;b&gt;Methods:&lt;/b&gt; MRI and clinical pathological data of patients confirmed by pathology as proliferative HCC (178 cases) and non-proliferative HCC (378 cases) between September 2017 and November 2022 who underwent preoperative Gd-EOB-DTPA enhanced MRI scans were retrospectively collected. The MRI features and clinical pathological characteristics of proliferative and non-proliferative HCC were evaluated. Multivariable logistic regression analysis was utilized to identify independent predictive factors for proliferative HCC, the R software was used to construct the nomogram prediction model, and its diagnostic performance was evaluated through receiver operating characteristic (ROC) curve. The calibration curve and decision curve analysis (DCA) were drawn to evaluate the calibration performance and clinical application value of the nomogram model. The optimal cut-off value was selected by calculating the Youden index to distinguish high risk and low risk. Kaplan-Meier survival curve was used to analyze the survival prognosis of proliferative and non-proliferative HCC, and log-rank test was used for comparison. &lt;b&gt;Results:&lt;/b&gt; There were significant differences in AFP level(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=17.244, &lt;i&gt;P&lt;/i&gt;&lt;0.001), morphology of tumor(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=13.669, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intertumoral fat(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=10.495, &lt;i&gt;P&lt;/i&gt;=0.001), arterial phase peritumoral enhancement(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=37.662, &lt;i&gt;P&lt;/i&gt;&lt;0.001), tumor capsule(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=23.961, &lt;i&gt;P&lt;/i&gt;&lt;0.001), substantial intratumoral necrosis(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=77.184, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral hemorrhage(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=4.892, &lt;i&gt;P&lt;/i&gt;=0.027), peritumoral hypointense in hepatobiliary phase(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=47.675, &lt;i&gt;P&lt;/i&gt;&lt;0.001), rim arterial phase hyperenhancement(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=115.976, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral artery(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=15.528, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and venous tumor thrombus(&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=10.532, &lt;i&gt;P&lt;/i&gt;=0.001) between proliferative and non-proliferative HCC groups. Multivariate Logistic regression analysis showed that AFP&gt;200 ng/ml(&lt;i&gt;OR&lt;/i&gt;=0.640, &lt;i&gt;P&lt;/i&gt;=0.044), no intertumoral fat(&lt;i&gt;OR&lt;/i&gt;=1.947, &lt;i&gt;P&lt;/i&gt;=0.033), substantial intratumoral necrosis(&lt;i&gt;OR&lt;/i&gt;=0.480, &lt;i&gt;P&lt;/i&gt;=0.003), peritumoral hypointense in hepatobiliary phase(&lt;i&gt;OR&lt;/i&gt;=0.432, &lt;i&gt;P&lt;/i&gt;=0.001), and rim arterial phase hyperenhancement(&lt;i&gt;OR&lt;/i&gt;=0.180, &lt;i&gt;P&lt;/i&gt;&lt;0.001) were independent predictors of preoperative diagnosis of proliferative HCC. Based on the independent predictors, a nomogram model for preoperative prediction of proliferative HCC was established. The area under the ROC curve of the model for predicting proliferative HCC was 0.772 (95%&lt;i&gt;CI&lt;/i&gt;: 0.735～0.807),","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[An excerpt for the management of congenital portosystemic shunts and their complications: EASL expert consensus (2023)].","authors":"N Zhang, G H Han","doi":"10.3760/cma.j.cn501113-20240708-00317","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240708-00317","url":null,"abstract":"<p><p>This article is an excerpt from the Expert Management of Congenital Portosystemic Shunts and Their Complications, which was published by the European Association for the Study of the Liver (EASL). Some of the most challenging systemic complications that often associated with congenital portosystemic shunts (CPSS) are liver nodules, pulmonary hypertension, endocrine abnormalities, and neurocognitive dysfunction. This article mainly provides expert clinical guidance for the management of liver nodules, pulmonary hypertension, and endocrine abnormalities, along with recommendations for shunt closure and follow-up.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"965-969"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on the role and mechanism of PANoptosis in liver diseases].","authors":"L Y Miao, X Wang, Y Y Han","doi":"10.3760/cma.j.cn501113-20240122-00048","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240122-00048","url":null,"abstract":"<p><p>Pyroptosis, apoptosis, and necroptosis are three key types of pathways in programmed cell death (PCD). Studies have found a wide range of cross-talk between the three types of pathways, leading to the proposal of the concept of PANoptosis, or the inflammatory PCD pathway regulated by the PANoptosome complex, which has key features of pyroptosis, apoptosis, and/or necroptosis that cannot be explained by any of these single pathways. A growing number of studies have discovered that PANoptosis is involved in many liver-related disease processes, including liver cancer, metabolic-associated fatty liver disease, liver failure, fulminant viral hepatitis, and others. Therefore, this paper reviews the potential mechanism and role of PANoptosis in order to provide directions for studying the pathogenesis and potential therapeutic strategies for a variety of liver-related diseases.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 11","pages":"1047-1052"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}